Stock Track | Amneal Pharmaceuticals Soars 9.95% in Pre-market After Q2 Earnings Beat and Raised Guidance

Stock Track07-30 18:28

Amneal Pharmaceuticals, Inc. (AMRX) shares surged 9.95% in pre-market trading on Thursday, following the release of its second-quarter 2026 financial results that exceeded analyst expectations.

The company reported adjusted earnings per share of $0.30, significantly beating the consensus estimate of $0.22. Revenue for the quarter rose 10% year-over-year to $796 million, also topping the analyst forecast of $768.2 million. GAAP net income more than doubled to $58 million, driven by strong performance in the specialty and affordable medicines segments. Additionally, Amneal raised its full-year 2026 guidance, now projecting revenue between $3.10 billion and $3.20 billion and adjusted EBITDA of $750 million to $780 million, both above prior ranges.

The pre-market rally reflects investor optimism around the company’s robust earnings beat and improved outlook, fueled by branded product growth and new product launches across its portfolio.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1104099187?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-30 18:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104099187","market":"us","top_or_hot":-1,"title":"Stock Track | Amneal Pharmaceuticals Soars 9.95% in Pre-market After Q2 Earnings Beat and Raised Guidance","media":"Stock Track","content":"<p>Amneal Pharmaceuticals, Inc. (AMRX) shares surged 9.95% in pre-market trading on Thursday, following the release of its second-quarter 2026 financial results that exceeded analyst expectations.</p><p>The company reported adjusted earnings per share of $0.30, significantly beating the consensus estimate of $0.22. Revenue for the quarter rose 10% year-over-year to $796 million, also topping the analyst forecast of $768.2 million. GAAP net income more than doubled to $58 million, driven by strong performance in the specialty and affordable medicines segments. Additionally, Amneal raised its full-year 2026 guidance, now projecting revenue between $3.10 billion and $3.20 billion and adjusted EBITDA of $750 million to $780 million, both above prior ranges.</p><p>The pre-market rally reflects investor optimism around the company’s robust earnings beat and improved outlook, fueled by branded product growth and new product launches across its portfolio.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Amneal Pharmaceuticals Soars 9.95% in Pre-market After Q2 Earnings Beat and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Amneal Pharmaceuticals Soars 9.95% in Pre-market After Q2 Earnings Beat and Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-30 18:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Amneal Pharmaceuticals, Inc. (AMRX) shares surged 9.95% in pre-market trading on Thursday, following the release of its second-quarter 2026 financial results that exceeded analyst expectations.</p><p>The company reported adjusted earnings per share of $0.30, significantly beating the consensus estimate of $0.22. Revenue for the quarter rose 10% year-over-year to $796 million, also topping the analyst forecast of $768.2 million. GAAP net income more than doubled to $58 million, driven by strong performance in the specialty and affordable medicines segments. Additionally, Amneal raised its full-year 2026 guidance, now projecting revenue between $3.10 billion and $3.20 billion and adjusted EBITDA of $750 million to $780 million, both above prior ranges.</p><p>The pre-market rally reflects investor optimism around the company’s robust earnings beat and improved outlook, fueled by branded product growth and new product launches across its portfolio.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMRX","symbol_name":"Amneal Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1104099187","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104099187","pubTimestamp":1785407310,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Amneal Pharmaceuticals, Inc. (AMRX) shares surged 9.95% in pre-market trading on Thursday, following the release of its second-quarter 2026 financial results that exceeded analyst expectations.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc."},"translate_title":"股票跟踪 | Amneal Pharmaceuticals 第二季度盈利超出预期并上调指引后盘前飙升 9.95%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMRX":1},"content_text":"Amneal Pharmaceuticals, Inc. (AMRX) shares surged 9.95% in pre-market trading on Thursday, following the release of its second-quarter 2026 financial results that exceeded analyst expectations.The company reported adjusted earnings per share of $0.30, significantly beating the consensus estimate of $0.22. Revenue for the quarter rose 10% year-over-year to $796 million, also topping the analyst forecast of $768.2 million. GAAP net income more than doubled to $58 million, driven by strong performance in the specialty and affordable medicines segments. Additionally, Amneal raised its full-year 2026 guidance, now projecting revenue between $3.10 billion and $3.20 billion and adjusted EBITDA of $750 million to $780 million, both above prior ranges.The pre-market rally reflects investor optimism around the company’s robust earnings beat and improved outlook, fueled by branded product growth and new product launches across its portfolio.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1104099187","isCrawlerRequest":true}